Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.

Leuk Lymphoma 2020 01 24;61(1):56-65. Epub 2019 Sep 24.

Genentech Inc, South San Francisco, CA, USA.

Exposure-response relationships from a phase 1b (M13-365) and phase 3 (MURANO) study were investigated to assess benefit/risk of venetoclax 400 mg daily plus rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dose intensities were summarized by tertiles of predicted venetoclax steady-state average concentrations based on nominal venetoclax dose () for tolerability; exposure-safety analyses used logistic regression. Exposure-progression-free survival (PFS) relationships were assessed using MURANO data, with as a grouping factor. Covariates were demographics, geographic region, study, baseline disease characteristics, ECOG performance status, responsiveness to prior therapy, and chromosomal abnormalities. There was no significant effect of covariates on grade ≥3 neutropenia/infection or PFS, and no relationship between venetoclax exposure and these endpoints, or venetoclax or rituximab dose intensity. These results support the recommended venetoclax 400 mg daily dose in combination with rituximab in patients with R/R CLL or small lymphocytic leukemia.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1657575DOI Listing
January 2020

Publication Analysis

Top Keywords

lymphocytic leukemia
12
phase murano
8
venetoclax 400 mg
8
400 mg daily
8
combination rituximab
8
chronic lymphocytic
8
rituximab patients
8
murano study
8
venetoclax
7
nominal venetoclax
4
venetoclax exposure
4
analyses logistic
4
logistic regression
4
venetoclax dose
4
exposure endpoints
4
exposure-safety analyses
4
based nominal
4
tolerability exposure-safety
4
performance status
4
dose tolerability
4

Similar Publications